Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-53718678 in pediatric RSV infection
CTR20210937Phase 2Terminated
- Sponsor
- Johnson & Johnson
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rilematovir in respiratory syncytial virus disease (RSV), sponsored by Johnson & Johnson. Started Jun 2021; status: terminated.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20210937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210937.